X

Trial Profile

Clinical and Biological Responses to Repeated Administration of Low-dose Interleukin-2 in Patients With Type 1 Diabetes and a Residual Insulin Secretion

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldesleukin (Primary) ; Ciclosporin (Primary)
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics
Acronyms DFIL2-REP

Most Recent Events

11 Aug 2023 Planned End Date changed from 1 Jul 2025 to 21 Jul 2026.
11 Aug 2023 Planned primary completion date changed from 1 Oct 2023 to 21 Oct 2024.
04 Nov 2022 Planned End Date changed from 1 Dec 2024 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com